Enzo Biochem Expands GoTestMeNow ™ Online Portal to Provide Patients with Direct Access to Private Testing for Sexually Transmitted Infections

0
  • GoTestMeNow ™ allows individuals to instantly and privately access physician-authorized tests for a wide range of STIs, including chlamydia, gonorrhea, syphilis, HIV-1/2, hepatitis and herpes

  • Expanded menu meets growing patient demand for direct access to other convenient diagnostic tests

NEW YORK, NY, October 21, 2021 (GLOBE NEWSWIRE) – Enzo Biochem, Inc. (NYSE: ENZ), a leading bioscience and diagnostics company, today announced the expansion of its online portal GoTestMeNow ™ to allow individuals to directly access physician-authorized laboratory tests for sexually transmitted infections (STIs). Previously, most consumers had to schedule diagnostic tests for STIs directly with a doctor during an office visit.

In many cases, patients delay or do not continue testing for many STIs due to privacy concerns and inconvenience. Using the GoTestMeNow portal (www.gotestmenow.com), individuals can now order and schedule medical tests to diagnose many different STIs on demand without the need for an in-person medical visit. Through GoTestMeNow, sample collection and testing services are provided through a network of Enzo Patient Service Centers in the New York / New Jersey metro area. Testing options include basic and extensive screenings that test for multiple STIs simultaneously as well as targeted testing options including chlamydia and gonorrhea, syphilis, herpes, HIV, and STIs during pregnancy. All tests are performed at the facilities of Enzo’s clinical laboratory in Farmingdale, NY. Patients get results through a secure online portal that is HIPAA compliant.

STIs represent a significant and growing health risk affecting millions of people every year. According to the Centers for Disease Control and Prevention (CDC), approximately 20 million new cases of STIs are reported each year in the United States. The incidence of STIs is also increasing. From 2015 to 2019, the number of CDC recorded cases of chlamydia, syphilis and gonorrhea was 2.5 million, an increase of almost 30%.

“Appropriate and accurate testing for STIs is one of the most difficult and important services in health care, but each year thousands of patients go undiagnosed or are not diagnosed until their symptoms stop. ‘aggravate. Many patients are reluctant to request diagnostic tests for STIs due to the inconvenience of having to visit a doctor for their testing needs, ”said Barry Weiner, President of Enzo. “Enzo’s GoTestMeNow online portal was successfully introduced in 2020 to support access to diagnostic testing for COVID-19 and is now being expanded to provide the same easy and quick access to testing for a wide range of patients. STIs, many of which require prompt diagnosis and treatment to avoid the risk of spreading infection and serious long-term health problems. This development is in line with our strategic approach of expanding testing beyond the central lab, including point-of-service platforms and direct-to-consumer offerings. “

Using the GoTestMeNow online portal, patients can organize STI testing through a streamlined process:

  • Individuals order the desired test online.

  • A licensed physician providing clinical oversight of GoTestMeNow services is promptly alerted for review and test authorization.

  • The online gateway facilitates all payment related needs.

  • Patients can go to the authorized testing location that best suits their needs. The website includes a full list of test sites (https://www.enzoclinicallabs.com/gotestmenow/).

  • Results are available, typically within three days, to patients through a secure HIPAA-compliant online patient portal.

  • A FAQ section on www.gotestmenow.com as well as phone and email contact options are available for patients to access additional information.

“The experience with COVID has modernized diagnostic testing by bringing solutions closer to the patient, and services like our GoTestMeNow demonstrate Enzo’s ability to innovate and change service models to meet patient needs,” added Mr. Weiner. “Enzo’s laboratory also has the infrastructure to meet all testing needs with a full range of high quality solutions in molecular diagnostics, immunoassays, immunohistochemistry and cytology.

To access COVID-19 testing services, patients can visit Enzo’s direct online portal at www.gotestmenow.com. Enzo’s diagnostic and laboratory services are backed by extensive data and research. Details on the Company’s full range of products and services are available at https://www.enzo.com.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem uses cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing healthcare needs of today and tomorrow. Enzo Biochem’s products and technologies are backed by a broad and in-depth intellectual property portfolio, with patent coverage on a number of key enabling technologies.

For more information, please visit www.Enzo.com or follow Enzo Biochem on Twitter and LinkedIn.

Forward-looking statements

With the exception of historical information, the matters discussed in this press release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act. of 1934, as amended. These statements include statements regarding the intention, beliefs or current expectations of the Company and its management, including those relating to cash flows, gross margins, revenues and expenses which depend on a number of factors. factors beyond the control of the Company, including, but not limited to, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation and general business conditions. See Risk Factors in the Company’s Form 10-K for the year ended July 31, 2021. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties. that could materially affect actual results. The Company disclaims any obligation to update any forward-looking statement as a result of developments occurring after the date of this press release.

###

Contact:

For: Enzo Biochem, Inc .:

David Bench, Chief Financial Officer
212-583-0100
[email protected]

Media:

Lynn granito
Public Relations Berry & Company
211-253-8881
[email protected]

Investors:

Bob Yedid
LifeSci Advisors, LLC
646-597-6989
[email protected]

Steve anreder
Anreder & Company
212-532-3232
[email protected]


Source link

Leave A Reply

Your email address will not be published.